<DOC>
	<DOC>NCT00392548</DOC>
	<brief_summary>Study of the urinary vascular endothelial growth factor (VEGF) levels in patients with glioblastoma, receiving standard therapy. Hypothesis: that urinary VEGF levels can serve as a predictor of treatment response and survival.</brief_summary>
	<brief_title>URINARY VEGF Levels in GBM Patients on Radiation Treatment Protocol</brief_title>
	<detailed_description>Measurement of urinary VEGF levels pre treatment,immediately after treatment, and 1 month after treatment</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>Patient must be enrolled on an RTOG GBM study that prescribes 6000 cGy of radiation therapy. Patient must meet the eligibility requirements for the RTOG treatment study. (If the patient is deemed retrospectively ineligible for the RTOG treatment study, the patient will likewise be ineligible for this study.) Patient must sign a studyspecific informed consent for RTOG 0611 prior to study entry. Patient not able to receive 6000 cGy of radiation therapy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>GBM</keyword>
	<keyword>glioblastoma</keyword>
	<keyword>urine</keyword>
	<keyword>VEGF</keyword>
	<keyword>radiation</keyword>
	<keyword>Patients must be enrolled to an RTOG GBM study that prescribes 6000 cGy of radiation therapy.</keyword>
</DOC>